Record · inventcures.github.io
A phase 2 trial to evaluate the efficacy and safety of WZTL-002, a third-generation anti-CD19 CAR T-cell therapy, in patients with relapsed or refractory large B-cell lymphoma (ENABLE-2).
$whoami : echo “tp53(ashish), ml + {medicine, biology} tinkerer” - tp53(ashish)’s home on the interwebs · 30 September 2026 · 2 min read
A post on inventcures.github.io, published 30 September 2026, has not been cited by any blog yet (corpus.blog, measured 13 October 2026).
A record is what was published and who pointed at it. The text of the post is not shown here: read it at the source, or at its Wayback capture.
0blogs citing
| Period | Blogs | Links |
|---|---|---|
| All time | 0 | 0 |
| Last 90 days | 0 | 0 |
| Last 30 days | 0 | 0 |
| Last 7 days | 0 | 0 |
| Words blogs link it with | 0 |
|---|---|
| External links | 0 |
| Length | 379 |
Cited by
No blog we hold has cited this post yet.
Links from this post
This post links to no other pages.
Similar posts
Q&A October is ECTRIMS Month
multiple-sclerosis-research.org
1 Oct 2026
CAR-T cell therapy
multiple-sclerosis-research.org
3 Oct 2026
Can hand function be a main endpoint in trials. I f hope so
multiple-sclerosis-research.org
21 Sept 2026
CAR-T Made easy
multiple-sclerosis-research.org
6 Sept 2026
Trial of the Year…Oh Please
multiple-sclerosis-research.org
4 Sept 2026
Something wrong here? Report a problem